Published online before print January 25, 2007, doi: 10.1161/01.STR.0000258347.19449.0f
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:1104.)
© 2007 American Heart Association, Inc.
Comments, Opinions, and Reviews |
High-Density Lipoprotein Cholesterol
An Emerging Target for Stroke Treatment
From the Department of Neurology (N.S.), University of Southern California, Los Angeles, Calif; the Stroke Center and Department of Neurology (J.L.S., B.O.), University of California Los Angeles (UCLA) Medical Center, Los Angeles, Calif; the Department of Medicine (M.N.), UCLA Medical Center, Los Angeles, Calif; and the Department of Neurology (B.O.), Olive View UCLA Medical Center, Los Angeles, Calif.
Correspondence to Nerses Sanossian, MD, Department of Neurology, University of Southern California, 1200 N State St, #5640, Los Angeles, CA 90033. E-mail sanossia{at}yahoo.com
 |
Abstract |
|---|
Top
Abstract
IntroductionBackground and Purpose— This review characterizes the current state of knowledge of high-density lipoprotein (HDL) in relation to stroke.
Summary of Review— HDL has anti-atherosclerotic and anti-inflammatory properties and is an important component in atherosclerosis. Serum HDL-cholesterol levels are inversely related to heart disease and stroke risk. There are various established and experimental treatments which can raise serum HDL cholesterol and improve its function.
Conclusion— HDL is an emerging target for atherosclerotic stroke treatment with the potential to dramatically impact the care of stroke patients.
Key Words: cholesterol • lipids & lipoprotein • stroke
|
Introduction |
|---|
Atherothrombosis is the leading cause of death worldwide through its manifestations as ischemic heart and cerebrovascular disease. Although several therapies that specifically target atherosclerotic disease have been shown in clinical trials to lower the risk of vascular events including stroke, it is clear that additional therapeutic options that can mitigate the burden of vascular disease on society need to be identified.
One such potential therapeutic option may be boosting the concentration or enhancing the function of high-density lipoprotein cholesterol (HDL). HDL is intimately involved in atherosclerosis and is a promising target for risk-modifying interventions aimed at limiting vascular disease. This review characterizes the current state of knowledge about HDL, including its structure, function, and diagnostic tests, its contribution to cerebrovascular disease, and its potential role as a therapeutic target to modify vascular risk in stroke patients.
|
HDL: Structure and Function |
|---|
Lipoproteins are complexes of proteins, phospholipids and cholesterol. HDL is the smallest and densest of the lipoproteins because of its high protein content. Proteins make up about 50% of its mass and apolipoprotein A-I (apoA-I) accounts for 70% of that protein component.
ApoA-I is a 243 amino acid protein synthesized in the liver (70%) and intestine (30%) and secreted into the serum in a lipid-free state. Individual apoA-I molecules associate with other apoA-I molecules, membrane phospholipids and cholesterol to form lipid-poor pre–ß-HDL. Lipid-poor HDL assumes a double-belt–like structure which becomes spherical with maturation and addition of cholesterol.1
Lipid-poor ß-HDL is able to take up cholesterol from artery wall macrophages via the ATP-binding cassette A-1 (ABCA-1) receptor.2 Cholesterol is transferred into lipid poor HDL and is then esterified by the enzyme lecithin-cholesterol acyltransferase. As cholesterol is esterified it is packaged into the core of the HDL leading to formation of the mature spherical lipoprotein.
Mature spherical HDL can then unload its cholesterol by 2 main mechanisms. Transfer of cholesterol back to the liver is facilitated by interaction with the scavenger receptor-B1 (SR-B1) receptor on hepatocytes and leads to formation of bile and secretion into the gut. Alternatively, cholesterol can be transferred from mature HDL to low-density lipoprotein (LDL) or very-low-density lipoprotein (VLDL), a process dependent on cholesteryl ester transfer protein (CETP). This leads to a recycling of cholesterol, potentially back into the artery wall.
|
Mechanisms of Action |
|---|
There are several mechanisms by which HDL protects against atherosclerosis, including reverse cholesterol transport, antioxidant effects, anti-inflammatory effects, antithrombotic effects, and modification of endothelial function (Figure).3
|
In reverse cholesterol transport, cholesterol is transported by HDL from the artery wall to the liver for excretion. Cholesterol is removed from macrophages in the subintima of the vessel wall by the interaction of HDL with ABCA-1, SR-B1, or by passive diffusion. Once esterified, cholesterol in the HDL is then transported to the liver for excretion.
In contrast to Vitamin E, a far less potent antioxidant, HDL and apoA-1 are able to prevent lipid oxidation, a key mechanism in atherosclerosis in both cell-free and artery-wall coculture studies.4 HDL is a major carrier of lipid hydroperoxides and paraoxonase, an enzyme involved in preventing and reversing oxidative damage.
HDL blocks inflammation by acting as an antioxidant but also by limiting the expression of cytokines such as tumor necrosis factor–
and interleukin-1 that mediate upregulation of leukocyte endothelial adhesion molecules. This has been demonstrated in cell cultures where monocyte chemotactic activity can be blocked with the addition of normal functioning HDL.5
Finally, HDL may also reduce thrombotic risk through the inhibition of platelet activation and aggregation6 and may improve endothelial function by stimulating prostacyclin release.7
|
Epidemiology |
|---|
In the United States, low HDL (<40 mg/dL) is present in 35% of men and 15% of women. The prevalence of low HDL is expected to rise because of increasing rates of obesity, diabetes, and the metabolic syndrome.
|
Serum HDL Cholesterol and Coronary Risk |
|---|
The inverse relationship of serum HDL cholesterol (HDL-C) and coronary heart disease (CHD) has been well established in large prospective studies. Gordon and colleagues analyzed the relation between HDL-C and CHD incidence in 4 prospective American studies: the Framingham Heart Study (FHS), the Lipid Research Clinics Prevalence Mortality Follow-up Study, the Lipid Research Clinics Coronary Primary Prevention Trial (CPPT), and the Multiple Risk Factor Intervention Trial (MRFIT).8 A 1-mg/dL increase in HDL-C was associated with a significant 2% decrease in CHD risk in men (FHS, CPPT, and MRFIT) and a 3% decrease in women (FHS). In the FHS, HDL-C was the most potent lipid risk factor for cardiovascular disease.9 These findings were confirmed in subsequent studies.10
|
Serum HDL Cholesterol and Stroke Risk |
|---|
The inverse relationship between serum HDL-C and stroke risk has strengthened in light of more recent epidemiological studies. Large cohort studies which have addressed this question (Table 1) included the British cohort,11 the Honolulu heart program,12 the Atherosclerosis Risk in Communities (ARIC) study,13 Oyabe study,14 Dubbo study,15 Copenhagen city heart study16 and the Israeli Ischemic Heart Disease Study.17 Although using different HDL levels in comparison, most studies demonstrated a significant inverse association12,14–17 and others demonstrated nonsignificant trends11,13 toward an inverse relationship of serum HDL-C and ischemic stroke risk. The populations studied included middle-aged and elderly men and women from America, Australia, Europe, Hawaii, Israel and Japan. When taken together it seems clear that higher baseline levels of serum HDL-C lower the risk of subsequent ischemic stroke. Case-control studies have also demonstrated this inverse relationship.18,19
|
Low serum HDL-C levels may reflect a greater risk for atherosclerotic stroke, a hypothesis supported by a few case-control studies. A study of 240 consecutive patients with stroke or transient ischemic attack demonstrated that low serum HDL-C levels were more frequently seen in the setting of atherosclerotic large-vessel disease relative to other stroke subtypes, including small-vessel disease.20 In the NOMASS study of HDL the odds of having an atherosclerotic large-vessel stroke was 0.20 in those with HDL-C concentrations 
35 (0.08 to 0.5, P<0.001) versus 0.60 (0.42 to 0.85, P<0.01) for other stroke types.18 Similarly, the Group Health Cooperative study showed that odds of having a large-vessel atherothrombotic stroke was reduced (odds ratio=0.4) in the highest HDL-C quintile when compared with the lowest. The same association was not present for other stroke subtypes.21
This association of HDL with atherosclerotic stroke is further strengthened by a study of carotid plaque progression.22 In 1952 subjects followed for 7 years, low HDL-C was associated with a significant increase in carotid plaque volume by ultrasound. The association of low HDL with increased plaque volume was strengthened when patients on cholesterol-lowering agents were excluded and may indicate an independent effect of HDL-C.
Few studies have compared serum HDL-C against serum LDL-C to determine relative contributions to stroke risk. In one study of the very old (aged 85 years) low serum HDL-C was associated with an increased risk of stroke, cardiovascular disease, and mortality whereas LDL-C and total cholesterol had no association.23 On the other side of the age spectrum, a study of young stroke patients demonstrated that low HDL-C was the only serum lipid index associated with an increased risk of stroke.24
|
Measuring HDL Function: Better Than HDL-C Levels? |
|---|
Studies have shown variability among individuals in regards to HDL function. For example, the apoA1Milano variant has a prolonged residence time in plasma and improved function conferring protection from atherosclerosis. Variability in HDL function may help explain why some individuals with advanced atherosclerosis have very high HDL-C and why many heart attacks and strokes occur in individuals with normal HDL-C levels. Whereas normal HDL is anti-inflammatory, studies have shown that HDL from some patients with cardiovascular disease is dysfunctional and actually pro-inflammatory.25 Populations at risk of having dysfunctional HDL have been found to include those with metabolic syndrome26 and those with low HDL-C in the setting of hypertrigliceridemia.27
HDL function can be measured through a variety of assays including some which quantify its inflammatory/anti-inflammatory properties.5 It has been shown that the inflammatory/anti-inflammatory activity balance of HDL distinguished patients with CHD from control subjects better than serum HDL-C concentrations.28 There is also evidence that treatment with statins may favorably improve the function of HDL.28 The effects of HDL function on ischemic stroke, particularly atherosclerotic stroke have yet to be studied.
|
Treatment Strategies |
|---|
Current Guideline Recommendations
The Adult Treatment Panel (ATP) and American Diabetes Association (ADA) guidelines recommend that dyslipidemic therapy be geared at achieving target LDL-C goals in persons with low HDL-C levels and that serum HDL-C levels are a secondary target.29,30 The Expert Group on HDL, a working group reporting on low HDL-C levels, advised additional treatment with a fibrate or niacin in persons with diabetes, the metabolic syndrome, or HDL levels <40 mg/dL.31 The importance of raising HDL-C in reducing cardiovascular and stroke risk has also been highlighted in recent reviews.3,32
Raising Serum HDL-C
Raising serum HDL-C can decrease cardiovascular risk by 5.5% for each 1 mg/dL increment in baseline HDL-C.33 There are various pharmacological and nonpharmacological means to increase serum HDL-C.34 Lifestyle-associated improvement in HDL-C appear to be greatest in persons with the highest baseline HDL-C levels (60 mg/dL).35 Many of these lifestyle modifications have been shown to reduce overall stroke risk, but it is unclear what effect they will have in patients with low-HDL at the highest risk of cardiovascular disease.
Pharmacological Treatments
Fibrates
Fibrates are effective at raising HDL-C level and lowering triglyceride levels and are ligands for peroxisome proliferator-activated receptors (PPARs), nuclear receptors that regulate the expression of genes involved in glucose and lipid metabolism, inflammation, and endothelial function.36 Raising HDL and lowering triglycerides with gemfibrozil has been shown to reduce major cardiovascular events, even in the absence of LDL-lowering.37 The reduction in stroke risk with gemfirbozil treatment was evident after 6 months, and those with the lowest HDL-C at baseline seemed most likely to benefit from treatment.38
Niacin
Niacin doses of 1 to 2 g per day can increase in HDL-C of 20% to 30%. The extended-release (ER) niacin preparation niaspan is better tolerated, with fewer flushing episodes and none of the liver toxicity seen with other slow-release preparations. The flushing from niacin is attributable to release of prostaglandin D2. The flushing can be mitigated by several days of pretreatment with aspirin to inhibit formation of prostaglandin D2. Trials of niacin in cardiovascular disease have not evaluated stroke as an independent end point but have shown significant reductions in cardiac end points.39
Statins
Statins have been shown to reduce the risk of ischemic stroke by about 20% in multiple large studies.40 Each 10% reduction in LDL-C is estimated to reduce the risk of stroke by 15.6% (95% CI, 6.7 to 23.6).41 The effects of statin therapy on HDL-C vary based on the particular agent and dose used42; for example, high-dose rosuvastatin increased HDL-C by 14%43 whereas high-dose atorvastatin increased HDL-C by less than 3%.42 A study of in-hospital initiation of statin in stroke patients found no significant effect on HDL-C at 3 months from statin initiation.44 The effect of statins may vary among patients, with those with low HDL-C and elevated triglycerides more likely to benefit from statin therapy.40
Combination Therapy
Combination therapy may hold the key to the most dramatic increase in HDL-C, and combinations of statin and niacin have demonstrated 18% to 21% increase in HDL-C.45,46
The HDL Atherosclerosis Treatment Study (HATS) highlighted the benefits of combining statin therapy with niacin. The combination halted angiographic atherosclerosis progression and reduced major clinical events.45 Data from the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER-2) study demonstrated that ER-niacin added to statin therapy may halt the progression of atherosclerosis, as measured by carotid intima-media thickness among CHD patients with low HDL-C levels.47 After 1 year of treatment, mean carotid intima-media thickness increased in the statin-only group but not in those treated with ER niacin. The addition of ER-niacin to background statin was well-tolerated with adherence exceeding 90%.47
The National Institutes of Health (NIH) is sponsoring the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) trial which will evaluate the merits of simultaneously lowering LDL and raising HDL cholesterol levels, in patients randomized to ER-niacin plus simvastatin or to simvastatin alone. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial is testing fenofibrate plus a statin versus a statin alone in patients with type 2 diabetes.
Emerging Therapies
Several new agent classes are in development to raise HDL levels (Table 2). Three of the most promising agent classes actively being studied are:
|
CETP Inhibitors
CETP inhibitors block the enzyme that facilitates recirculation of cholesterol via VLDL and LDL. Partial inhibition of this enzyme is associated with an increase of HDL-C by up to 106%.48 CETP inhibitors may be more effective in combination with statins. Certain side effects, such as an increase in blood pressure, have been noted and clinical trials using the combination of atorvastatin and torcetrapib are underway.
ApoA-I Peptides
ApoA-I peptides are agents that improve HDL function by providing one of the substrates to HDL formation. Experimental evidence indicates that both over-expression of the apoA-I gene and direct infusion of apoA-I in animal models increase HDL-C levels and decrease atherosclerosis. The 2 main apoA-I peptides being studied are the apoA-IMilano complex and the D-4F peptide.
Injection of apoA-IMilano complex reduced the lipid content and inflammation of atherosclerotic lesions and induced regression of atherosclerosis in animal models.49 These results have since been replicated in humans.50 Using intravascular ultrasound, 5 weekly infusions of a recombinant version of apoA-IMilano produced a modest but significant 4% regression of coronary atherosclerosis in 47 acute coronary syndrome patients.
Short apoA-1 mimetic peptides created from D-amino acids such as D-4F have been shown to increase formation of pre–ß-HDL acutely. These peptides can be taken orally and have been shown to prevent atherosclerosis and block inflammation in experimental models.51
These classes of agents are promising in their ability to acutely boost HDL function in the setting of acute stroke and improve HDL metabolism and function. These agents are currently being tested in early human clinical trials.
PPAR Agonists
Large, buoyant HDL particles may be associated with reduced cardiovascular risks. The PPAR agonists, such as the glitazones, are known to have modest HDL-boosting effects although their main action is in reducing insulin resistance. A recent study suggested that pioglitazone increased the size and buoyancy of HDL particles in combination with other diabetic treatments in patients with type 2 diabetes.52 The percentage distribution of larger HDL particles (HDL 2) increased by 2% to 3% over the 24-week study period, whereas the smaller HDL particles (HDL 3) decreased by 1.5% to 2.5%. The NIH sponsored Insulin Resistance Intervention after Stroke (IRIS) trial is currently looking at the effect of pioglitazone in recent ischemic stroke patients.53
Acute Stroke Therapy
In addition to targeting chronic HDL elevation as a stroke prevention intervention, acute augmenting of HDL-C is promising as a therapy for acute ischemic stroke. HDL has been shown to reduce neuronal damage after onset of ischemic stroke, possibly by antioxidative/anti-inflammatory mechanisms, in both excitotoxic and middle cerebral artery occlusion models of stroke.54 Additionally, treatment with apoA-1 reduces brain lesion size by 64% in the middle cerebral artery occlusion model.55 Infusing HDL or apoA-1 into humans decreases inflammation, stabilizes plaque and has the potential to improve outcomes. Acute augmentation of HDL by direct infusion or by increasing apoA-1 may be a powerful neuroprotective tool acting via multiple mechanisms for the treatment of acute stroke.
High-dose statins are currently being studied in the setting of acute stroke, and one of their mechanisms of action may be in augmentation of HDL. Patients will be treated with very high doses of lovastatin (escalating dosage levels of 1, 3, 6, 8, and 10 mg/kg) for 3 days after acute stroke. Conventional dose lovastatin does increase HDL-C by 6%, and HDL increases may be greater at the planned high dose.56
|
Conclusions |
|---|
Atherosclerotic stroke is the end result of many different pathological processes in which HDL-C is a critical component. It is being increasingly recognized that low HDL-C is an important risk factor that is highly modifiable in relation to atherosclerosis. A strategy of HDL augmentation with the combination of statins and long-acting niacin may be the best means of raising serum HDL-C at present. However, although it may be reasonable to aim to increase HDL-C, it must be acknowledged that compelling proof of benefit from randomized clinical trials with clinical-event end points is not yet available.
On the basis of available evidence, it would seem reasonable to start all atherosclerotic stroke patients with HDL <40 on the combined statin and long-acting niacin therapy with the goal of increasing HDL by 20%. The future holds the promise of newer HDL-directed therapies with the potential to further boost serum HDL-C concentration and improve HDL-C function.
|
Acknowledgments |
|---|
Disclosures
None.
Received July 20, 2006; revision received September 26, 2006; accepted October 3, 2006.
|
References |
|---|
1. Lewis GF, Rader DJ. New insights into the regulation of hdl metabolism and reverse cholesterol transport. Circ Res. 2005; 96: 1221–1232.
2. Brewer HB Jr. Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein a1 transporter. Am J Cardiol. 2004; 92: 10–16.
3. Brewer HB Jr. Increasing HDL cholesterol levels. N Engl J Med. 2004; 350: 1491–1494.
4. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med. 2005; 353: 9–11.
5. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001; 42: 1308–1317.
6. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001; 104: 2376–2383.
7. Vinals M, Martinez-Gonzalez J, Badimon JJ, Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (COX-2). Arterioscler Thromb Vasc Biol. 1997; 17: 3481–3488.
8. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DRJ, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989; 79: 8–15.
9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. The Am J Med. 1977; 62: 707–714.[CrossRef]
10. Assmann G, Schultea H, Eckardsteinb AV, Huanga Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124: S11–S20.[CrossRef][Medline] [Order article via Infotrieve]
11. Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke. 2000; 31: 1882–1888.
12. Curb JD, Abbott RD, Rodriguez BL, Masaki KH, Chen R, Popper JS, Petrovitch H, Ross GW, Schatz IJ, Belleau GC, Yano K. High density lipoprotein cholesterol and the risk of stroke in elderly men: The Honolulu Heart Program. Am J Epidemiol. 2004; 160: 150–157.
13. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003; 34: 623–631.
14. Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: The OYABE study. Stroke. 2003; 34: 863–868.
15. Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for ischemic stroke: Dubbo study of the elderly. Stroke. 1998; 29: 1341–1346.
16. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ. 1994; 309: 11–15.
17. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality: a 21-year follow-up of 8586 men from the Israeli ischemic heart disease study. Stroke. 1997; 28: 83–87.
18. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L. High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan stroke study. JAMA. 2001; 285: 2729–2735.
19. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke. Stroke. 2003; 34: 2930–2934.
20. Laloux P, Galanti L, Jamart J. Lipids in ischemic stroke subtypes. Acta Neurol Belg. 2004; 104: 13–19.[Medline] [Order article via Infotrieve]
21. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004; 63: 1868–1875.
22. Johnsen SH, Mathiesen EB, Fosse E, Joakimsen O, Stensland-Bugge E, Njølstad I, Arnesen E. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression a follow-up study of 1952 persons with carotid atherosclerosis. Circulation. 2005; 112: 498–504.
23. Weverling-Rijnsburger AWE, Jonkers IJAM, Van Exel E, Gussekloo J, Westendorp RGJ. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med. 2003; 163: 1549–1554.
24. Albucher JF, Ferrieres J, Ruidavets JB, Guiraud-Chaumeil B, Perret BP, Chollet F. Serum lipids in young patients with ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry. 2000; 69: 29–33.
25. Fogelman AM. When good cholesterol goes bad. Nature Medicine. 2004; 10: 902–903.[CrossRef][Medline] [Order article via Infotrieve]
26. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, Kontush A. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004; 89: 4963–4971.
27. Kontusha A, Fariaa ECd, Chantepiea S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis. 2005; 182: 277–285.[CrossRef][Medline] [Order article via Infotrieve]
28. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003; 108: 2751–2756.
29. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001; 285: 2486–2497.
30. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004; 27: 68S–71.[CrossRef][Medline] [Order article via Infotrieve]
31. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol. 2004; 43: 717–724.
32. Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Engl J Med. 2005; 353: 1252–1260.
33. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention trial. Circulation. 1986; 74: 1217–1225.
34. Fleming RM. The effect of high-, moderate-, and low-fat diets on weight loss and cardiovascualr disease risk factors. Prev Cardiol. 2002; 5: 110–118.[Medline] [Order article via Infotrieve]
35. Williams PT. The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism. 2004; 53: 700–709.[CrossRef][Medline] [Order article via Infotrieve]
36. Bloomfield HE. The role of fibrates in a statin world. Arch Intern Med. 2006; 166: 715–716.
37. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999; 341: 410–418.
38. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention trial (VA-HIT). Circulation. 2001; 103: 2828–2833.
39. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol. 2004; 15: 659–665.[CrossRef][Medline] [Order article via Infotrieve]
40. Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004; 3: 271–278.[CrossRef][Medline] [Order article via Infotrieve]
41. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004; 35: 2902–2909.
42. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). The Am J Cardiol. 2003; 92: 152–160.
43. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif J-C, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; for the AI. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA. 2006; 295: 1556–1565.
44. Sanossian N, Saver JL, Liebeskind DS, Kim D, Razinia T, Ovbiagele B. Achieving target cholesterol goals after stroke: is hospital initiation the key? Archives of Neurology. 2006; 63: 1081–1083.
45. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Serafini L, Huss-Frechette E, Wang S, DeAngelis D, Dodek A, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001; 345: 1583–1592.
46. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323: 1289–1298.[Abstract]
47. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. Circulation. 2004; 110: 3512–3517.
48. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004; 350: 1505–1515.
49. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B. Effects of recombinant apolipoprotein A-imilano on aortic atherosclerosis in apolipoprotein E–deficient mice. Circulation. 1998; 97: 780–785.
50. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003; 290: 2292–2300.
51. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005; 25: 1325–1331.
52. Khan M, Perez A, Goldberg R, Spanheimer R, Jacober S. Subanalysis of the comparative effects of pioglitazone and rosiglitazone on markers of diabetic dyslipidemia in elderly patients with type 2 diabetes and dyslipidemia (ABS). Endocr Pract. 2006; 12: 18–19.[Medline] [Order article via Infotrieve]
53. Insulin resistance intervention after stroke (IRIS) trial. Available at: http://www.Iristrial.org/. Accessed January 17, 2007.
54. Paterno RRA, Postiglione A, Hubsch A, Andresen I, Lang MG. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis. 2004; 17: 204–211.[Medline] [Order article via Infotrieve]
55. Paterno R, Ruocco A, Cicale M, Ferraro P, Baiano A, Spagnuolo G, Ferrara F, Postiglione A. Acute neuroprotective effect of high-density lipoprotein in experimental models of cerebral stroke (ABS). Stroke. 2006; 37: 729.
56. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr; for the ATRG. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. JAMA. 1998; 279: 1615–1622.
This article has been cited by other articles:
 |
|
 |
|
  A. Murray, C. Cluett, S. Bandinelli, A. M. Corsi, L. Ferrucci, J. Guralnik, A. Singleton, T. Frayling, and D. Melzer Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people Eur. Heart J., July 2, 2009; 30(14): 1711 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sacks, L. L. Rudel, A. Conner, H. Akeefe, G. Kostner, T. Baki, G. Rothblat, M. de la Llera-Moya, B. Asztalos, T. Perlman, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J. Lipid Res., May 1, 2009; 50(5): 894 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Newman, H. Bang, S. I. Hussain, and J. F. Toole Association of diabetes, homocysteine, and HDL with cognition and disability after stroke Neurology, November 27, 2007; 69(22): 2054 - 2062. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||